PDF herunterladen
Semin Liver Dis 2004; 24: 17-21
DOI: 10.1055/s-2004-828674
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The Natural History of Chronic Hepatitis B Virus Infection

Brian J. McMahon1
  • 1Director, Viral Hepatitis Program, Alaska Native Medical Center, Anchorage, Alaska
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
11. Juni 2004 (online)

    Lizenzen und Reprints

Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic hepatitis B phase, and the inactive hepatitis B carrier phase. Active liver disease is most often found in persons with elevated aminotransferase levels and HBV DNA levels >105 copies/mL. Possible risk factors for developing liver disease include older age, male gender, presence of hepatitis B e antigen (HBeAg), HBV genotype, mutations in the precore and core promoter regions of the viral genome, and coinfection with hepatitis D (delta) virus. All persons chronically infected with HBV should be followed every 6 to 12 months with aminotransferase levels. Those with elevated levels should be tested for HBeAg and its antibody (anti-HBe) as well as HBV DNA levels to determine if they are in need of further evaluation with a liver biopsy and are candidates for antiviral therapy. Future research will help clarify the outcome of chronic HBV infection.

KEYWORDS

Hepatitis B virus - natural history - hepatocellular carcinoma

REFERENCES

  • 1 Lok A S, McMahon B J. Chronic hepatitis B: update of recommendations. AASLD Practice Guideline.  Hepatology. 2004;  39 857-861
    CrossrefPubMedGoogle Scholar
  • 2 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000. Summary of a workshop.  Gastroenterology. 2001;  120 1828-1853
    PubMedGoogle Scholar
  • 3 Lee P I, Chang M H, Lee C Y et al.. Changes in serum hepatitis B DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children.  Hepatology. 1990;  12 657-660
    PubMedGoogle Scholar
  • 4 Bortolotti F, Cadrobbi P, Crivellaro C et al.. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B infection in childhood.  Gastroenterology. 1990;  99 805-810
    PubMedGoogle Scholar
  • 5 McMahon B J, Holck P, Bulkow L, Snowball M M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus.  Ann Intern Med. 2001;  135 759-768
    CrossrefPubMedGoogle Scholar
  • 6 Hadziyannis S J, Vassilopoulos D. Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection.  Antiviral Res. 2001;  52 91-98
    CrossrefPubMedGoogle Scholar
  • 7 Brunetto M R, Oliveri F, Rocca G et al.. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen.  Hepatology. 1989;  10 198-202
    PubMedGoogle Scholar
  • 8 Okamoto H, Tsuda F, Akahane Y et al.. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen.  J Virol. 1994;  68 8102-8110
    PubMedGoogle Scholar
  • 9 McMahon B J. Chronic carriers of hepatitis B virus who clear hepatitis B surface antigen: are they really “off the hook?”.  Hepatology. 1998;  28 265-267
    CrossrefPubMedGoogle Scholar
  • 10 Harpaz R, McMahon B J, Margolis H S et al.. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program.  J Infect Dis. 2000;  181 413-418
    CrossrefPubMedGoogle Scholar
  • 11 Chang M H, Chen C J, Lai M S et al.. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children.  N Engl J Med. 1997;  336 1855-1859
    CrossrefPubMedGoogle Scholar
  • 12 Chu C J, Keeffe E B, Han S Y et al.. Hepatitis B virus genotypes in the United States: Results of a nationwide study.  Gastroenterology. 2003;  125 444-451
    CrossrefPubMedGoogle Scholar
  • 13 Koa J H, Chen P J, Lai M Y, Chen D S. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection.  J Clin Microbiol. 2002;  40 1207-1209
    CrossrefPubMedGoogle Scholar
  • 14 Sumi H, Yokosuka O, Seki N et al.. Influence of hepatitis B virus genotypes on the progression of chronic hepatitis B liver disease.  Hepatology. 2003;  37 19-26
    CrossrefPubMedGoogle Scholar
  • 15 Chu C J, Lok A SF. Clinical significance of hepatitis B virus genotypes.  Hepatology. 2002;  35 1274-1276
    CrossrefPubMedGoogle Scholar
  • 16 Chu C J, Keeffe E B, Han S Y et al.. Prevalence of HBV precore/core promoter variants in the United States.  Hepatology. 2003;  38 619-628
    PubMedGoogle Scholar
  • 17 Hadziyannis S J, Papatheodoridis G V, Vassilopoulos D. Precore mutant chronic hepatitis B-approach to management.  Medscape Gen Med Gastroenterology. 2003;  4 1-12 , Available at: www.medscape.com/viewarticle/459763 Accessed November 4, 2003
    PubMedGoogle Scholar
  • 18 McMahon B J, Bulkow L, Harpster A et al.. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study.  Hepatology. 2000;  32 842-846
    CrossrefPubMedGoogle Scholar
  • 19 Farci P. Delta hepatitis: an update.  J Hepatol. 2003;  39 S212-S219
    CrossrefPubMedGoogle Scholar

Brian J McMahonM.D. 

4055 Tudor Centre Drive

Anchorage, AK 99508-5902

eMail: bdm9@cdc.gov